{
    "id": 4878,
    "name": "esophageal adenoid cystic carcinoma",
    "source": "DOID",
    "definition": "An esophageal carcinoma that derives_from epithelial cells of the salivary gland. [url:http\\://en.wikipedia.org/wiki/Adenoid_cystic_carcinoma]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:4878",
    "evidence": [
        {
            "id": 11800,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, esophageal cancer cells with MYC amplification demonstrated sensitivity to Imbruvica (ibrutinib), resulting in reduced MYC expression, cell-cycle arrest, and decreased survival in culture (PMID: 28830912).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 4878,
                "name": "esophageal adenoid cystic carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9793,
                    "pubMedId": 28830912,
                    "title": "Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28830912"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        
    ]
}